Boehringer Ingelheim granted condition approval for valvular disease treatment
by Katie Pfaff
Animal product company, Boehringer Ingelheim Animal Health, has been granted conditional approval for VETMEDIN®-CA1 (pimobendan), a treatment for dog valvular disease from the FDA’s Administration Center for Veterinary Medicine. The drug is indicated to slow the onset of certain chronic heart ailments in dogs.
The medication has been indicated for staving off disease onset for congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). Results of a recent study found that the treatment extended life without symptoms by an average of 15 months when compared to placebo.
"We are thrilled to expand our pet therapeutic portfolio to include an option for dogs with asymptomatic canine valve disease," said Shawn Hooker, head of US Pet Business at Boehringer Ingelheim Animal Health. "We understand the importance in early treatment to delay the onset of symptoms related to heart failure to help dogs continue to engage in the daily activities they enjoy."
In addition, the medication is approved for symptom management in dogs with MMVD and mild, moderate, or severe congestive heart failure. The therapy is also indicated as an additive for other treatment as evaluated per case.
Comments
Tag
Related Articles
More news
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment